Patent · US Active

RBM3 as a marker for malignant melanoma prognosis

US8632984B2 · kind B2 · utility

1Cited by

0References

10Claims

0Family size

Assignee

Atlas Antibodies AB · SE

Inventors

Mathias Uhlen · Uppsala, SE
Fredrik Pontén · Uppsala, SE
Karin Jirström · Malmö, SE

Key dates

Filing date	Dec 17, 2009
Grant date	Jan 21, 2014
Priority date	—
Expiry date	Dec 17, 2029

Classification

Technology area (CPC G)Physics
CPC primaryG01N33/5743
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

A method for determining whether a mammalian subject having a malignant melanoma belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group is provided. The method comprises the steps of: evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.